Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 285 mio. sales in 2021

€ 1.10 per share dividend paid in 2022

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Investor News

  • In the third quarter of 2022, preliminary IFRS consolidated revenue rose by 1.2% to EUR 67.2 million compared to the second quarter of 2022 (EUR 66.4 million).

  • The operating result (EBIT) of EUR 2.3 million in Q3/22 is almost at the level of the previous quarter (EUR 2.4 million).

  • Compared to the previous year 2021, Group turnover for the first nine months decreased from EUR 216.6 million to EUR 188.2 million, as expected. The main reasons for the decline in turnover are the absence of the special effects from the extensive Corona test business of the previous year.

  • Group EBIT as of 30.09.2022 amounts to EUR 6.7 million (previous year 30.09.2021: EUR 8.6 million).
  • The equity ratio increases from 79.5% to 82.4% as of 30.09.2022.

  • The forecast for the current financial year is confirmed unchanged. EBIT of EUR 8 million to EUR 10 million is expected for 2022.  

Rating & Research

Warburg Research

Buy: 30.00 €

First Berlin Equity Research

Buy: 35.00 €


Zum Aktienchart

Safely and well advised


Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports


We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

Investor News

HAEMATO AG increased its revenue in the second quarter of 2022 by EUR 11.9 million compared to the first quarter of 2022 to EUR 66.4 million. The operating result (EBIT) increased from EUR 2.0 million to EUR 2.4 million in this period.

Investor News

HAEMATO AG announces figures for the first quarter of 2022. According to these figures, the Group's consolidated revenue fell to EUR 54.6 million in the first quarter (previous year: EUR 73.9 million). EBITDA fell from EUR 2.8 million in the same quarter of the previous year to EUR 2.3 million. EBIT amounted to EUR 2.0 million in the first …

Investor News

Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General …

Upcoming events

Financial calendar

Date Event
13 April 2023 Preliminary figures for the 2022 financial year
17 May 2023 Annual Report 2022
31 May 2023 Q1 Results 2023
18 July 2023 Annual Shareholders‘ Meeting FY 2022 in Berlin
31 August 2023 Interim Report 2023
16 November 2023 Q3 Results 2023

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us